ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Investment

AbbVie and Voyager form Parkinson’s pact

by Ryan Cross
March 1, 2019 | APPEARED IN VOLUME 97, ISSUE 9

 

AbbVie has struck a second partnership with the neuroscience-focused gene-therapy firm Voyager Therapeutics. AbbVie is paying Voyager $65 million up front to develop gene therapies that contain instructions for making antibodies against the α-synuclein protein that accumulates in the brains of people with Parkinson’s disease. Voyager could earn up to $245 million in milestone payments after preclinical and Phase I clinical studies, and nearly $1.3 billion in added milestone payments. Last year, the two companies formed a similar pact to develop an Alzheimer’s gene therapy.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment